Fujifilm gets $265M contract from BARDA, partners with Novavax

Fujifilm Diosynth Biotechnologies will receive $265 million in federal money to manufacture COVID-19 vaccines as part of Operation Warp Speed

The Tokyo-based drugmaker also will manufacture 100 million vials of Novavax’s experimental coronavirus vaccine at its facility in Morrisville, N.C., the Washington Business Journal reported. 

The doses are being earmarked for Novavax’s phase 3 trial, which will include 30,000 people in the U.S.

More articles on pharmacy:
Pfizer CEO calls drug pricing executive orders ‘radical,’ an ‘enormous distraction’
10 best-selling drugs in the world by 2026
Walgreens says 180 stores affected by potential patient data breach

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.